Tags

Type your tag names separated by a space and hit enter

Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease--a randomized, placebo-controlled, double-blind cross-over trial.
J Intern Med Suppl 1989; 731:225-32JI

Abstract

Thirty-nine patients with chronic inflammatory bowel disease were studied in a 7-month, double-blind, placebo controlled cross-over trial of dietary supplementation with fish oil, which provided about 3.2 g n-3 fatty acids per day. At control, biopsies from inflamed mucosa contained higher levels of arachidonic acid than uninvolved mucosa. Dietary n-3 fatty acids were well tolerated and incorporated into plasma and enteric mucosa phospholipids at the expense of n-6 fatty acids. The arachidonic acid-derived prostanoid generation was reduced by fish oil and the extension and severity of macroscopic bowel involvement was moderately improved. In patients with Crohn's disease, clinical activity was unchanged by fish-oil supplementation. In patients with ulcerative colitis, clinical disease activity fell during fish oil supplementation and thereafter; this was not significant however. Despite a moderate reduction in inflammatory lipid mediators by dietary n-3 fatty acids and limited morphological improvement in chronic inflammatory bowel disease, the clinical benefit seems to be confined to patients with ulcerative colitis.

Authors+Show Affiliations

Medical Clinic Innenstadt, Munich 2, FRG.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Comparative Study
Journal Article
Randomized Controlled Trial
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

2650694

Citation

Lorenz, R, et al. "Supplementation With N-3 Fatty Acids From Fish Oil in Chronic Inflammatory Bowel Disease--a Randomized, Placebo-controlled, Double-blind Cross-over Trial." Journal of Internal Medicine. Supplement, vol. 731, 1989, pp. 225-32.
Lorenz R, Weber PC, Szimnau P, et al. Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease--a randomized, placebo-controlled, double-blind cross-over trial. J Intern Med Suppl. 1989;731:225-32.
Lorenz, R., Weber, P. C., Szimnau, P., Heldwein, W., Strasser, T., & Loeschke, K. (1989). Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease--a randomized, placebo-controlled, double-blind cross-over trial. Journal of Internal Medicine. Supplement, 731, pp. 225-32.
Lorenz R, et al. Supplementation With N-3 Fatty Acids From Fish Oil in Chronic Inflammatory Bowel Disease--a Randomized, Placebo-controlled, Double-blind Cross-over Trial. J Intern Med Suppl. 1989;731:225-32. PubMed PMID: 2650694.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Supplementation with n-3 fatty acids from fish oil in chronic inflammatory bowel disease--a randomized, placebo-controlled, double-blind cross-over trial. AU - Lorenz,R, AU - Weber,P C, AU - Szimnau,P, AU - Heldwein,W, AU - Strasser,T, AU - Loeschke,K, PY - 1989/1/1/pubmed PY - 1989/1/1/medline PY - 1989/1/1/entrez SP - 225 EP - 32 JF - Journal of internal medicine. Supplement JO - J Intern Med Suppl VL - 731 N2 - Thirty-nine patients with chronic inflammatory bowel disease were studied in a 7-month, double-blind, placebo controlled cross-over trial of dietary supplementation with fish oil, which provided about 3.2 g n-3 fatty acids per day. At control, biopsies from inflamed mucosa contained higher levels of arachidonic acid than uninvolved mucosa. Dietary n-3 fatty acids were well tolerated and incorporated into plasma and enteric mucosa phospholipids at the expense of n-6 fatty acids. The arachidonic acid-derived prostanoid generation was reduced by fish oil and the extension and severity of macroscopic bowel involvement was moderately improved. In patients with Crohn's disease, clinical activity was unchanged by fish-oil supplementation. In patients with ulcerative colitis, clinical disease activity fell during fish oil supplementation and thereafter; this was not significant however. Despite a moderate reduction in inflammatory lipid mediators by dietary n-3 fatty acids and limited morphological improvement in chronic inflammatory bowel disease, the clinical benefit seems to be confined to patients with ulcerative colitis. SN - 0955-7873 UR - https://www.unboundmedicine.com/medline/citation/2650694/full_citation L2 - https://medlineplus.gov/crohnsdisease.html DB - PRIME DP - Unbound Medicine ER -